Flavocure Biotech announced it raised $215,000 in an initial filing from an offering of $2 Million

Company

Location

About

Flavocure was founded with a focus on non-cannabinoid bioactive phytochemical properties of cannabis. The company recently discovered Creserol, a drug which recently received Orphan Drug approval by the FDA for the treatment of Acute Myeloid Leukemia. In collaboration with some of the top research institutions in the world, the company continues to embark on discoveries with the use of other drugs for the treatment pancreatic cancer and glioblastoma brain cancer. Most recently has established ongoing collaboration with Harvard Medical School and the Dana Farber Cancer Institute, as well as ongoing research with the University of Maryland Medical School and Duke University.